Debt holders mount pressure on Valeant
24 Apr 2016Canadian drug company Valeant Pharmaceuticals (Valeant) has received further notices of default from its bondholders, in connection with the company’s delay in filing its audited annual results for 2015.
Under the notice, relating to four bonds maturing between 2020
